


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Sitagliptin. [Updated 2019 Feb 7]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Sitagliptin

Revised: February 7, 2019.

CASRN: 486460-32-6



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of sitagliptin during breastfeeding. Sitagliptin has a shorter halflife than most other dipeptidyl-peptidase IV inhibitors, so it might be a better choice among drugs in this class for nursing mothers. Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with saxagliptin.[1] However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

Substance Identification

Substance Name

Sitagliptin

CAS Registry Number

486460-32-6

Drug Class

Breast Feeding Lactation Hypoglycemic Agents Incretins Dipeptidyl-Peptidase IV Inhibitors DPP-4 Inhibitors